AngioDynamics Files 8-K on Financials

TL;DR

ANGI filed an 8-K, expect financial updates soon.

AI Summary

On July 16, 2024, AngioDynamics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational details were provided in the excerpt.

Why It Matters

This filing indicates AngioDynamics is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.

Risk Assessment

Risk Level: low — This is a routine SEC filing reporting financial information and does not inherently present new risks.

Key Players & Entities

• AngioDynamics, Inc. (company) — Registrant
• July 16, 2024 (date) — Date of earliest event reported
• 14 Plaza Drive, Latham, New York 12110 (address) — Principal Executive Offices
• 518-795-1400 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share ANGO NASDAQ Global Select

Filing Documents

• ef20032494_8k.htm (8-K) — 33KB
• ef20032494_ex99-1.htm (EX-99.1) — 1241KB
• 0001140361-24-033240.txt ( ) — 1452KB
• ango-20240716.xsd (EX-101.SCH) — 4KB
• ango-20240716_lab.xml (EX-101.LAB) — 21KB
• ango-20240716_pre.xml (EX-101.PRE) — 16KB
• ef20032494_8k_htm.xml (XML) — 4KB

02 – Results of Operations and Financial Condition

Item 2.02 – Results of Operations and Financial Condition. AngioDynamics, Inc. ("AngioDynamics") is voluntarily providing pro forma condensed combined financial statements as of and for the fiscal quarters ended August 31, 2022, November 30, 2022 and February 28, 2023, August 31, 2023, November 30, 2023 and February 29, 2024, as described in Item 9.01 below, giving effect to the completion of the sale of AngioDynamics' dialysis and BioSentry businesses to Merit Medical Systems, Inc. on June 8, 2023, as previously disclosed on AngioDynamics' Current Report on Form 8-K filed with the Securities and Exchange Commission on June 14, 2023, the sale of AngioDynamics' PICC and Midline product portfolios to Spectrum Vascular on February 24, 2024 and the discontinuation of the RadioFrequency ablation and Syntrax support catheter products as of February 29, 2024 (collectively, the "Businesses"). The pro forma financial information included with this report in Item 9.01 (including Exhibit 99.1) has been presented for informational purposes only and is incorporated by reference into this Item 2.02. The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Forward-Looking Statements

Forward-Looking Statements This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects", "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of produ

01 – Financial Statements and Exhibits

Item 9.01 – Financial Statements and Exhibits. (b) Pro forma financial information . Attached hereto as Exhibit 99.1 and incorporated by reference is the following unaudited pro forma financial information, in each case giving pro forma effect to the sale of the Businesses, for each of the three-month periods ended August 31, 2022, November 30, 2022 and February 28, 2023, August 31, 2023, November 30, 2023 and February 29, 2024: unaudited pro forma consolidated income statements; net sales and gross profit by product category; and notes to the unaudited pro forma consolidated financial statements. (d) Exhibits . Exhibit No. Description 99.1 Unaudited Pro Forma Financial Information SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANGIODYNAMICS, INC. (Registrant) Date: July 16, 2024 By: /s/ Stephen A. Trowbridge Name: Stephen A. Trowbridge Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR